Pricing Log in Create free account

Allogene Therapeutics, Inc. (ALLO) vs Contineum Therapeutics, Inc. (CTNM)

Allogene Therapeutics, Inc. and Contineum Therapeutics, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Contineum Therapeutics, Inc. are of similar size ($504.4M and $503.4M). Contineum Therapeutics, Inc. has the higher net margin (0.00% vs −3,517.4%) and the lower return on invested capital (−1,334.4% vs −108.8%). Across the 12 metrics below, Contineum Therapeutics, Inc. leads on 8 and Allogene Therapeutics, Inc. on 4.

Valuation

Metric ALLO CTNM Biotechnology median
P/E n/m n/m 8.56
P/S 98.57 n/m 10.17
P/B 1.06 1.37 2.34
Price to free cash flow n/m n/m 20.42
EV/EBITDA n/m n/m 0.69
EV/Sales 27.88 n/m 9.64
Earnings yield (47.52%) (19.75%) (29.41%)
Free cash flow yield (22.12%) (16.29%) (23.50%)

Profitability

Metric ALLO CTNM Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (3,832.45%) 0.00% 0.00%
Net margin (3,517.41%) 0.00% 0.00%
Free cash flow margin (2,180.62%) 0.00% 0.00%
Return on equity (42.39%) (28.01%) (56.66%)
Return on assets (32.43%) (26.57%) (49.22%)
Return on invested capital (108.81%) (1,334.41%) 0.00%

Growth

Metric ALLO CTNM Biotechnology median
Revenue growth (TTM) 7,613.11% — 5.64%
EPS growth (last fiscal year) 34.09% 0.46% 30.08%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ALLO CTNM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.72 37.17 4.72
Net debt to EBITDA 1.24 3.88 0.96

Dividend

Metric ALLO CTNM Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric ALLO CTNM Biotechnology median
Market cap 504.42m 503.37m 151.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack